ResearcherJohannes Gutenberg University MainzActive in the last 2 years
Hauke Lang
Matched on ORCID iD 0000-0001-9303-2148; OpenAlex author ID A5048426715. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 14
2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper
Papers 5
- REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
- [Lymphadenectomy in oncological visceral surgery-Part 1 : Hepatobiliary tumors and pancreatic cancer]. Last author DOI 10.1007/s00104-019-0956-7↗
- Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette s… Co-author DOI 10.1186/s12885-019-5889-5↗
- Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits. First author DOI 10.3390/ijms18081622↗
- Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III s… Co-author DOI 10.1186/1471-2407-11-346↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Stefan Heinrich · 4 shared papers, 2011–2019 · strength 0.40
- Paper Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits. DOI 10.3390/ijms18081622↗
- Paper [Lymphadenectomy in oncological visceral surgery-Part 1 : Hepatobiliary tumors and pancreatic cancer]. DOI 10.1007/s00104-019-0956-7↗
- Paper Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: … DOI 10.1186/s12885-019-5889-5↗
- F. Bartsch · 1 shared paper, 2019 · strength 0.14
- Markus Hermann Moehler · 2 shared papers, 2011–2019 · strength 0.12
- Paper Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: … DOI 10.1186/s12885-019-5889-5↗
- Paper Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic canc… DOI 10.1186/1471-2407-11-346↗
- Mickaël Lesurtel · 2 shared papers, 2011–2019 · strength 0.12
- Paper Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: … DOI 10.1186/s12885-019-5889-5↗
- Paper Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic canc… DOI 10.1186/1471-2407-11-346↗
- Jean‐Luc Van Laethem · 1 shared paper, 2019 · strength 0.09
- Manfred Paul Lutz · 1 shared paper, 2019 · strength 0.09
- Marc G. Besselink · 1 shared paper, 2019 · strength 0.09
- Michel Pierre Ducreux · 1 shared paper, 2019 · strength 0.09
- Jean‐Robert Delpéro · 1 shared paper, 2011 · strength 0.02
- Frederik Christiaan Berrevoet · 1 shared paper, 2011 · strength 0.02
- Pierre‐Alain Clavien · 1 shared paper, 2011 · strength 0.02
- Philippe Bachellier · 1 shared paper, 2011 · strength 0.02
- Patrick Dufour · 1 shared paper, 2011 · strength 0.02
- Jean‐Luc Raoul · 1 shared paper, 2011 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.